Evidence map›Paper›PMID 29691690›Full record

ReviewZeitschrift fur Rheumatologie2018

[Biomarkers and imaging for diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the BMBF consortium ArthroMark].

T Häupl, A Skapenko, B Hoppe, K Skriner, H Burkhardt, D Poddubnyy, S Ohrndorf, P Sewerin, U Mansmann, B Stuhlmüller and 2 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Rheumatologie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

T HäuplMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland. thomas.haeupl@charite.de.
A SkapenkoSektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, München, Deutschland.
B HoppeZentralinstitut für Laboratoriumsmedizin und Pathobiochemie, Charité, Berlin, Deutschland.
K SkrinerMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland.
H BurkhardtAbteilung für Rheumatologie, Johann-Wolfgang-Goethe-Universität, Frankfurt, Deutschland.
D PoddubnyyMedizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Berlin, Deutschland.
S OhrndorfMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland.
P SewerinMedizinische Klinik für Endokrinologie, Diabetologie und Rheumatologie, Heinrich-Heine-Universität, Düsseldorf, Deutschland.
U MansmannInstitut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität, München, Deutschland.
B StuhlmüllerMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland.
H Schulze-KoopsSektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität, München, Deutschland.
G-R BurmesterMedizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité-Universitätsmedizin Berlin, Campus Mitte (CCM), Charitéplatz 1, 10117, Berlin, Deutschland.
Charité - Universitätsmedizin Berlin · DELudwig-Maximilians-Universität München · DEGoethe University Frankfurt · DEHeinrich Heine University Düsseldorf · DEZimmer Biomet (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatic diseases are among the most common chronic inflammatory disorders. Besides severe pain and progressive destruction of the joints, rheumatoid arthritis (RA), spondyloarthritides (SpA) and psoriatic arthritis (PsA) impair working ability, reduce quality of life and if treated insufficiently may enhance mortality. With the introduction of biologics to treat these diseases, the demand for biomarkers of early diagnosis and therapeutic stratification has been growing continuously. The main goal of the consortium ArthroMark is to identify new biomarkers and to apply modern imaging technologies for diagnosis, follow-up assessment and stratification of patients with RA, SpA and PsA. With the development of new biomarkers for these diseases, the ArthroMark project contributes to research in chronic diseases of the musculoskeletal system. The cooperation between different national centers will utilize site-specific resources, such as biobanks and clinical studies for sharing and gainful networking of individual core areas in biomarker analysis. Joint data management and harmonization of data assessment as well as best practice characterization of patients with new imaging technologies will optimize quality of marker validation.

Indexed as

Early DiagnosisArthritis, PsoriaticArthritis, RheumatoidAutoantibodiesBiomarkersDiagnostic ImagingDisability EvaluationGenotypeHumansInterdisciplinary CommunicationIntersectoral CollaborationQuality of LifeSpondylarthritisAutoantibodiesBiomarkersAbility to workPsoriatic arthritisQuality of lifeRheumatoid arthritisSpondyloarthritides

Identifiers

PMID29691690
OpenAlexW2799671358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.